Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT05079464
Recruiting Not applicable

Exercise as a Primer for Brain Stimulation in Vascular Cognitive Impairment No Dementia (VCIND)

NCT05079464 · tracked via the Priya Life Science Canada tracker
Sponsor
Sunnybrook Health Sciences Centre
Phase
Not applicable
Started
2021-11-22
Last updated
2026-04-13

Condition(s) studied

Vascular Cognitive ImpairmentMild Cognitive Impairment

Investigational drug(s) / intervention(s)

tDCSExerciseSham stimulationTreatment as usual

tDCS: All participants randomized to tDCS will receive active tDCS

Exercise: Participants will exercise at Toronto Rehab.

Sham stimulation: The same procedure for tDCS will be used for the sham condition, except without active current.

Treatment as usual: Exercise education/ treatment as usual will include routine advice about physical activity.

Study summary

People with vascular conditions are at risk of having memory problems, and these memory problems increase the risk for further cognitive decline. Brain stimulation has been used to improve mood and memory. Transcranial direct current stimulation (tDCS) is believed to work best on brain cells that are active or "primed" before stimulation. The purpose of this study is to compare the effects of exercise and tDCS on memory performance in patients who have completed cardiac rehabilitation and are at risk of cognitive decline.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * ≥50 years of age; females must be post-menopausal * Presence of cerebrovascular and/or cardiovascular risk factors or coronary artery disease * Montreal Cognitive Assessment (MoCA) \<27 * Sufficiently proficient in English * Must be able to exercise at a moderate intensity level * Presence of modest deficits (1 standard deviation below population norm) in one of the following domains: executive function, verbal memory, working memory, or visuospatial memory Exclusion Criteria: * History of stroke * Change in psychotropics within the last 4 weeks * Current benzodiazepine use due * Metal implants that would preclude safe use of tDCS or neuroimaging * Significant neurological or psychiatric conditions (current major depressive disorder, bipolar disorder, schizophrenia) * MoCA \<18 and/or clinical diagnosis of dementia * Any medical contraindications to exercise

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sunnybrook Health Sciences Centre Toronto Ontario Recruiting

More Sunnybrook Health Sciences Centre trials in Canada

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study Recruiting
Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study Recruiting
Using Cannabis to Treat Restless Legs Syndrome Recruiting
A Randomized Neuroimaging Trial of Psilocybin in Depression Recruiting
Comparing Virtual Reality Simulation to High Fidelity Simulation as an Educational Modality for Electroconvulsive Therapy Training: A Non-Inferiority Study Recruiting

Other trials for the same condition

The Brain Health PRO Online Risk Factor Reduction Study to Prevent Dementia Recruiting
Deep TMS for Comorbid Depression and Cognitive Impairment in Older Adults Recruiting
Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers Recruiting
Memory Support System Feasibility Study Recruiting
Alzheimer's Disease Neuroimaging Initiative 4 Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05079464 on ClinicalTrials.gov ↗ ← All trials in Canada